Showing 2411-2420 of 5623 results for "".
- Zeiss Introduces New Devices and Software Applications as Part of Medical Ecosystemhttps://modernod.com/news/zeiss-introduces-a-series-of-innovations-and-software-applications-as-part-of-the-medical-ecosystem/2480290/As part of its innovation week, Zeiss introduced integrated solutions designed to bring value to the Zeiss Medical Ecosystem, connecting devices, data, and applications. Zeiss introduced a new integrated cataract workflow solution for lens replacement with the launch of t
- Results Published From 2-year Multicenter Study Illustrate Efficacy and Safety of Preserflo MicroShunthttps://modernod.com/news/results-published-from-2-year-multicenter-study-illustrate-efficacy-and-safety-of-preserflo-microshunt/2480287/Santen EMEA has announced the results from a 2-year multicenter study of the Preserflo MicroShunt in patients with primary open-angle glaucoma (POAG). The study showed that mean IOP was significantly reduced from 21.7±3.4 mmHg at baseline to 14.1±3.2 mmHg at year 2 (&
- Comorbid Ophthalmic, Systemic Conditions Linked With Higher Risk of Dementiahttps://modernod.com/news/comorbid-ophthalmic-systemic-conditions-linked-with-higher-risk-of-dementia/2480281/People with both ophthalmic and systemic conditions were found to be at higher risk of dementia compared with those with only 1 such condition, according to a report in the American Journal of Managed Care. Some ophthalmic condition
- MeiraGTx Announces Data at EURETINA 2021 Demonstrating Reversal of Disease Progression Following Treatment With AAV5-RPGR in XLRPhttps://modernod.com/news/meiragtx-announces-data-at-euretina-2021-demonstrating-reversal-of-disease-progression-following-treatment-with-aav5-rpgr-in-xlrp/2479499/MeiraGTx Holdings announced new data from subjects treated in the phase 1/2 dose escalation phase of Study MGT009 indicating AAV5-RPGR, an investigational gene therapy in development for the treatment of X-linked retinitis pigmentosa (XLRP), reverses course of disease progression when retinal fun
- Coburn Technologies Launches Waterless Lens Deblocking System and Alloy Recovery Systemhttps://modernod.com/news/coburn-technologies-launches-waterless-lens-deblocking-system-and-alloy-recovery-system/2479494/Coburn Technologies has officially launched the Reimagine Campaign to announce new technology advancements in lens processing. Coburn has developed a completely waterless lens deblocking system and a first-of-its-kind alloy recovery system for labs that use alloy for lens processing.
- Amydis Receives NIH Grant to Develop a Novel Tau Retinal Tracer for Alzheimer’s Diseases and Other Tauopathieshttps://modernod.com/news/amydis-receives-nih-grant-award-to-develop-a-novel-tau-retinal-tracer-for-alzheimers-diseases-and-other-tauopathies/2479481/Amydis announced a new phase 1 grant award from the National Institute of Aging at the National Institutes of Health (NIH) to support the development of a novel small-molecule retinal tracer targeting the biomarker tau for the detection and diagnosis of Alzheimer’s disease and other tauopathies.<
- Maxwell Hosts Recipients of Opening Your Eyes: The Vision Council Scholarship Fundhttps://modernod.com/news/maxwell-hosts-recipients-of-opening-your-eyes-the-vision-council-scholarship-fund/2479480/Last week, three-time Grammy winner, and modern soul star, Maxwell, honored three recipients of the “Opening Your Eyes: The Vision Council Scholarship Fund” at the Times Square EDITION hotel. During the celebratory event, Maxwell, on behalf of The Vision Council, presented three of th
- Complexity Gaming Kicks Off Year-Long Partnership With Alconhttps://modernod.com/news/complexity-gaming-kicks-off-year-long-partnership-with-alcon/2479475/Esports company Complexity Gaming announced a partnership with Alcon. The partnership will designate Alcon’s signature brand of lubricant eye drops, Systane, as the first official eye care partner of Complexity Gaming. Now more than ever, dry eye symptoms are affecting people due to increa
- Journal Highlights Desirable PK/PD Profiles of THR-687 and THR-149https://modernod.com/news/journal-highlights-desirable-pk-pd-profiles-of-thr-687-and-thr-149/2479450/Oxurion NV announced the publication of two related papers in the Journal of Pharmacokinetics and Pharmacodynamics entitled “Systemic exposure following intravitreal administration of therapeutic agents: an integrated pharmacokinetic approach.” These papers describe the pharmacoki
- Regeneron Terminates Ocular Therapeutix Collaboration to Develop a Sustained-Release Formulation of Aflibercepthttps://modernod.com/news/regeneron-terminates-ocular-therapeutix-collaboration-to-develop-a-sustained-release-formulation-of-aflibercept/2479441/Ocular Therapeutix announced that Regeneron has terminated the option and license agreement collaboration between the companies. The termination became effective August 5, 2021. The collaboration with Regeneron was initially formed in 2016 for the development and commercialization of produ